FDA-cleared profile

Lung-CAD

Imagen Technologies, Inc · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: Lung-CAD is a concurrent-read computer-aided detection aid for identifying and marking regions of interstitial thickening on adult chest radiographs; it does not provide a clinical diagnosis or replace physician review or other tests.

Clinical role
Analyzes a chest radiograph and returns DICOM presentation-state overlays or a no-ROI message for concurrent physician review.
Images and patients
X-ray/Radiography · Chest/Lung
Key limitation
Keep in mind: Adults and interstitial thickening on chest radiographs only; the software is a concurrent aid, not a diagnosis or replacement for physician review, other tests, or clinical judgment, and false positives or negatives remain possible.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Lung-CAD is a concurrent-read computer-aided detection aid for identifying and marking regions of interstitial thickening on adult chest radiographs; it does not provide a clinical diagnosis or replace physician review or other tests.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest/Lung Input: Adult chest radiographs received through the supported DICOM radiography workflow.
  • Who uses it?Intended users: Physicians and other qualified healthcare professionals interpreting adult chest radiographs.
  • What does the software produce?Output: DICOM Presentation State with deep-learning regions of interest labeled interstitial thickening, or the text message No Lung-CAD ROI(s) when no region is marked.
  • What is its most important limitation?Key limitation: Adults and interstitial thickening on chest radiographs only; the software is a concurrent aid, not a diagnosis or replacement for physician review, other tests, or clinical judgment, and false positives or negatives remain possible.

Clinical takeaway. Clinical role: Lung-CAD is a concurrent-read computer-aided detection aid for identifying and marking regions of interstitial thickening on adult chest radiographs; it does not provide a clinical diagnosis or replace physician review or other tests.

Evidence takeaway. Evidence from the reviewed source record: K223811 FDA material reports standalone testing on 5,000 chest radiograph cases with sensitivity 0.913, specificity 0.866, and ROC AUC 0.961 for the labeled interstitial-thickening endpoint; these values are exact-study metrics, not a general clinical outcome claim.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Lung-CAD is a concurrent-read computer-aided detection aid for identifying and marking regions of interstitial thickening on adult chest radiographs; it does not provide a clinical diagnosis or replace physician review or other tests.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Analyzes a chest radiograph and returns DICOM presentation-state overlays or a no-ROI message for concurrent physician review.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Adult chest radiographs received through the supported DICOM radiography workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
DICOM Presentation State with deep-learning regions of interest labeled interstitial thickening, or the text message No Lung-CAD ROI(s) when no region is marked.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospital and radiology chest-radiography workflows.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Physicians and other qualified healthcare professionals interpreting adult chest radiographs.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Adults and interstitial thickening on chest radiographs only; the software is a concurrent aid, not a diagnosis or replacement for physician review, other tests, or clinical judgment, and false positives or negatives remain possible.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
K223811 FDA material reports standalone testing on 5,000 chest radiograph cases with sensitivity 0.913, specificity 0.866, and ROC AUC 0.961 for the labeled interstitial-thickening endpoint; these values are exact-study metrics, not a general clinical outcome claim.
  • Exact FDA submission
  • Checked 2026-09-04

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K223811 FDA material reports standalone testing on 5,000 chest radiograph cases with sensitivity 0.913, specificity 0.866, and ROC AUC 0.961 for the labeled interstitial-thickening endpoint; these values are exact-study metrics, not a general clinical outcome claim.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
95%
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-13

Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.

Interstitial-thickening sensitivity

0.913 proportion

  • EndpointStandalone case-level sensitivity
  • Population5,000 chest radiograph cases
  • Tested versionLung-CAD configuration described in K223811

Interstitial-thickening specificity

0.866 proportion

  • EndpointStandalone case-level specificity
  • Population5,000 chest radiograph cases
  • Tested versionLung-CAD configuration described in K223811

Interstitial-thickening ROC AUC

0.961 ROC AUC

  • EndpointStandalone discrimination
  • Population5,000 chest radiograph cases
  • Tested versionLung-CAD configuration described in K223811

K223811 FDA evidence package for Lung-CAD

  • DesignFDA 510(k) standalone performance evaluation of the exact deep-learning chest-radiograph detector.
  • Population5,000 adult chest radiograph cases with positive and negative interstitial-thickening reference labels.
  • Scopeexact submission
  • Tested versionLung-CAD configuration described in K223811
  • Samplen=5000
  • IndependenceSponsor or vendor study

K223811

The FDA summary reports a 2.5% positive-case prevalence in the test cohort; the endpoint is detection of interstitial thickening, not diagnosis or patient outcome.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K223811 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult chest radiographs received through the supported DICOM radiography workflow.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K223811: Lung-CAD

  2. Routing

    Source context, not route validation: The FDA material describes DICOM input and DICOM Presentation State output with per-image regions of interest or a no-ROI message.

    Scope: Exact FDA submission. This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K223811: Lung-CAD

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: DICOM Presentation State with deep-learning regions of interest labeled interstitial thickening, or the text message No Lung-CAD ROI(s) when no region is marked.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K223811: Lung-CAD

  5. Viewer/worklist/report

    Unresolved route: DICOM Presentation State with deep-learning regions of interest labeled interstitial thickening, or the text message No Lung-CAD ROI(s) when no region is marked.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K223811: Lung-CAD

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The FDA material describes DICOM input and DICOM Presentation State output with per-image regions of interest or a no-ROI message.
  • Exact FDA submission
  • Checked 2026-09-04

This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

Security
Imagen's security policy (effective 2024-04-02) states HIPAA, HITRUST CSF and SOC 2 Type II compliance, encryption in transit and at rest, least-privilege access, multi-factor authentication, audit trails and incident response. Vendor statement; no report or certificate was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: the policy is on imagen.ai, whose AI software page lists this product by name, and the FDA letter for this entry names Imagen Technologies, Inc. (New York). The policy is company-wide; exact-release scope is not established. A 2023 HITRUST release names the Care Delivery Services platform, not the devices, and is not applied.

Training
Only Physicians and other qualified healthcare professionals interpreting adult chest radiographs should operate or interpret the product; local onboarding must cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K223811 by exact hardware, software, model, algorithm version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Adults and interstitial thickening on chest radiographs only; the software is a concurrent aid, not a diagnosis or replacement for physician review, other tests, or clinical judgment, and false positives or negatives remain possible.
  • Exact FDA submission
  • Checked 2026-09-04

Buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K223811 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA material describes DICOM input and DICOM Presentation State output with per-image regions of interest or a no-ROI message.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Adults and interstitial thickening on chest radiographs only; the software is a concurrent aid, not a diagnosis or replacement for physician review, other tests, or clinical judgment, and false positives or negatives remain possible.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K223811 by exact hardware, software, model, algorithm version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K223811
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Chest/Lung
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-09-13
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
32Fields reviewed
11Source classes checked
14Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

Screened 14 PubMed and one ClinicalTrials.gov record. They concern M5L or other lung CAD and CT systems rather than Imagen Technologies Lung-CAD or K223811; all 15 were quarantined and none was promoted. The current discovery snapshot contains 14 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K223811: Lung-CAD

    U.S. Food and Drug Administration - Published 2023-09-13 - Accessed 2026-09-04

    Scope: identity, productIdentity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Lung-CAD model card (K223811)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: anatomy

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  8. Imagen Security Policy

    Imagen Technologies - Published 2024-04-02 - Accessed 2026-10-26

    Scope: security

Research history

  1. K223811 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K230085

Lung-CAD

Imagen Technologies, Inc

Authorized purpose: Lung-CAD is a computer-assisted detection (CADe) software device that analyzes chest radiograph studies for lung hyperinflation. The device uses a deep learning algorithm to identify regions of interest (ROIs) with lung hyperinflation and produces boxes around the ROIs. Lung-CAD is intended for use as a concurrent reading aid for physicians interpreting chest X-rays. The device is not intended for clinical diagnosis of any disease. It does not replace the role of the physician or of other diagnostic testing in the standard of care for lung parenchymal findings. Lung-CAD is indicated for adults only.

Modality
X-ray/Radiography
Anatomy
Chest/Lung
Decision
2023-10-03
FDA-cleared K243831

Rayvolve LN

AZmed

Authorized purpose: Second-reader support for radiologists reviewing adult digital AP or PA chest radiographs, with suspected pulmonary nodules in the 6-30 mm range marked for review.

Modality
X-ray/Radiography
Anatomy
Chest/Lung
Decision
2025-03-26
FDA-cleared K243808

Rayvolve PTX-PE

AZmed

Authorized purpose: Passive study-level worklist triage for suspected pneumothorax and/or pleural effusion on adult PA or AP chest X-rays; it is not a proactive specialist alert.

Modality
X-ray/Radiography
Anatomy
Chest/Lung
Decision
2025-03-21

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history